Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?
Open Access
- 1 February 2023
- journal article
- research article
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 8 (1) , 5-11
Abstract
Obesity and nonalcoholic fatty liver disease (NAFLD) constitute global and growing epidemics that result in therapeutic dead ends. There is an urgent need for new and accessible treatments to improve and widen both preventive and curative approaches against NAFLD. The endocannabinoid system (ECS) is recognized as a complex signaling apparatus closely related to metabolic disorders and is a key target for treating NAFLD. Despite a lack of conclusive clinical trials, observational and pre-clinical studies highlight putative benefits of phytocannabinoids on liver steatosis through multiple pathways. Owing to both its safety profile and its diversity of active compounds acting primarily (although not exclusively) on the ECS—and its expanded version, the endocannabinoidome, the Cannabis plant should be considered a major prospect in the treatment of NAFLD. However, seizing this opportunity, and intensifying clinical research in this direction, will require overcoming both scientific and nonscientific barriers.Keywords
This publication has 66 references indexed in Scilit:
- Beneficial Metabolic Effects of CB1R Anti-Sense Oligonucleotide Treatment in Diet-Induced Obese AKR/J MicePLOS ONE, 2012
- Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin ResistanceCell Metabolism, 2012
- CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humansInternational Journal of Obesity, 2012
- Cannabinoids mediate opposing effects on inflammation‐induced intestinal permeabilityBritish Journal of Pharmacology, 2011
- Rimonabant: From RIO to BanJournal of Obesity, 2011
- The endocannabinoid system: Its roles in energy balance and potential as a target for obesity treatmentThe International Journal of Biochemistry & Cell Biology, 2010
- Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesityJournal of Clinical Investigation, 2010
- Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver FatArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis CGastroenterology, 2008
- Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa ratsHepatology, 2007